Daxor Corporation Common Stock (DXR)
Business numbers score is above the middle — price trend score is below the middle.
DXR scores higher than 61% of the 1,101 tickers we compare it with (Health Care).
As of 10 October 2026, Daxor Corporation Common Stock (DXR) scores 46 out of 100 on the Market Census six-factor composite, which puts it at the Average score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 10 October 2026, and it is not investment advice.
Updated · scores usually change about once a day
Key statistics
Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.
- Relative volume
- 0.21× 30-day average
- 52-week range
- 8.56 – 14.76
- Market cap
- $61.48M
- Earnings date
- —
- Volume
- 7,457
- Avg. volume (30d)
- 34,919
- Open
- 10.51
- Previous close
- 10.46
- Day's range (regular session)
- 10.41 – 10.71
The last trade can be an extended-hours trade, so it can sit outside the regular-session range.
Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.
- Beta
- 0.35
- P/E (TTM)
- 6.42
- EPS (TTM)
- 1.98
Score breakdown · six named factors
Each bar is one part of the score, from 0 to 100. Read what the score means.
Premium data held for DXR
- 1 SEC Form 4 insider transaction in the last 90 daysPremium
Counts of rows Market Census holds for DXR. A dash in the factor table above means that factor has no data for this ticker — it is not a locked value. Compare plans
What the score says about DXR right now
Daxor Corporation Common Stock (DXR) currently scores 46/100 on the Market Census six-factor composite, at the Average score level. DXR is -0.48% on the day and -1.98% over five sessions as of the most recent tick. Average sits in the middle. The good and the bad in DXR's data roughly balance out right now. DXR's strongest factor is company finances at 73/100 — a strong read on the company's own reported numbers. A high reading doesn't promise a near-term move. The weakest factor is price trend at 34/100 — a below average technical read. If the rest of the picture is good, a soft price trend often reflects a re-test of support rather than structural breakdown — descriptively, not as a call to act.
Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.
See DXR in the scanner
This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).
Recent DXR news
Latest headlines that name Daxor, one per story, sourced from Market Census’s news feed (Polygon/Massive + Finnhub).
- Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026Yahoo
- Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth ConferenceYahoo
- Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder LetterYahoo
- Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in KansasGlobeNewswire Inc.
Saved snapshot; the news and prices on this page can be an hour old or more.
Similar setups in Health Care right now
Six health care tickers whose composite scores are closest to DXR’s 46, all within 1 point.
Sorted by closeness to DXR’s composite score within Health Care. Saved snapshot; can be an hour old or more. Run the full scanner →
Prices delayed about 15 minutes; scores usually change about once a day. Not investment advice — see risk disclosure.